Moneycontrol PRO
you are here: HomeNewsWorld

Coronavirus pandemic: India is not the only country to ban Chinese kits. Here are some others

India procured around five lakh rapid antibody test kits from two Chinese firms and they were distributed to several states reporting rising cases of the coronavirus infection.

April 28, 2020 / 05:19 PM IST

Beijing is stepping up its oversight of export of coronavirus test kits after several European countries complained about the accuracy of some Chinese-made tests, news agency Reuters has reported.

India had, on April 27, asked its states and Union Territories to stop using the rapid antibody COVID-19 testing kits procured from China due to "wide variation" in their performance.

India procured around five lakh rapid antibody test kits from two Chinese firms, Guangzhou Wondfo Biotech and Livzon Diagnostics, and they were distributed to several states reporting rising cases of the coronavirus infection.

Also Read: Cops over 55 years can stay home, says Mumbai Police after 3 die of COVID-19

Now, according to the news agency, Chinese exporters of coronavirus tests must obtain a registration certificate from the National Medical Products Administration (NMPA) in order to be cleared by China’s customs, the NMPA said in a statement late on Tuesday.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Beijing had been encouraging Chinese firms to export test kits and other supplies to help battle the coronavirus pandemic, leading to a surge of companies offering kits to countries desperate to get a handle on the fast-moving and highly contagious disease.

Some Chinese test kit makers had been taking advantage of easier European Union regulations to get their products into the market before they were approved at home.

In March, Lei Chaozi, an official with the Ministry of Education, said China-made testing kits had already been supplied to 11 countries, including the UK, Italy and the Netherlands.

Follow our LIVE Updates here.

Which other countries, apart from India, have withdrawn Chinese testing kits?

The accuracy of some Chinese tests marketed overseas without Chinese approval have been questioned by European health authorities.

Spain withdrew a batch of rapid tests manufactured by Chinese diagnostics firm Shenzhen Bioeasy Biotechnology after the product was found to have low sensitivity, which means they were unable to detect infection sufficiently.

Bioeasy said in a statement last week the inaccurate readings could be because samples were not collected and processed correctly. Bioeasy said it failed to adequately communicate with clients on how to use the test.

Separately, a spokeswoman from China’s foreign ministry said last week that Slovak government officials had questioned the reliability of rapid tests purchased from China.

Also Read | Delhi eases lockdown; plumbers, electricians can return to work

The preliminary conclusion from the Chinese consulate in Slovakia was that the inaccuracies were the result of medical workers using the kit incorrectly, the spokeswoman said.

The Slovak government did not immediately respond to requests for comment.

Antigen tests 

Bioeasy's rapid tests, as well as the tests questioned by Slovak officials, are antigen tests, a method that targets the virus' protein to detect infection and can deliver results more quickly than the alternative nucleic acid method.

But antigen tests require higher level of virus load and therefore could fail to diagnose people correctly when the samples only contain small amount of virus, Dr. Chen Guangjie, an immunology professor at Shanghai Jiaotong University, told Reuters.

New coronavirus test makers in China are entering the European market during a transition between two regulatory systems.

Also Read | WHO warns lifting of coronavirus lockdowns must be gradual

A stricter rule will come into force in 2022 that will require many infectious disease diagnostic product manufacturers to follow procedures that can take up to a year or more to get a CE mark that indicates approval to be legally sold in European countries.

Current regulations used by several Chinese companies allow manufacturers to obtain CE Mark after submitting a dossier of documents without compulsory verification by authorised third-parties.

Now, China's tightened scrutiny is interrupting test manufacturers' overseas expansion plans.

Xi'an Tianlong Science and Technology, a Chinese firm which received the CE Mark in March and has been in the process of churning out testing reagents that can supply tests for over one million people, told Reuters it now can't meet its export orders.

"Our reagents don't have (NMPA) certificate and cannot be exported," the company's marketing director Feng Zhenzhen said, adding the firm is "actively" applying for Chinese regulator's approval.

Also Read: In Charts | Economic impact of lockdown on Centre and states

Jam Chan, marketing general manager at Osmunda, a service firm that advises Chinese medical product firms on getting overseas approvals, said many recently developed tests in China haven't gone through strict clinical trials, which means the self-declared accuracy rate printed on the products is not properly validated.

"Better not exporting products than offering inaccurate products that can lead to fake results," said Chan. "The quality of products that have been through domestic review before being exported is at least guaranteed to some extent."

Click here to get all the news on the coronavirus pandemic
Moneycontrol News
first published: Apr 28, 2020 05:19 pm
ISO 27001 - BSI Assurance Mark